SCHEMBL24596185

SCHEMBL24596185

Fc1ccc(Nc2nc(C(F)(F)F)ccc2Br)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 7/20 0.38
MAPK1 P28482 1/20 0.38
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
LRRK2 Q5S007 1/20 0.36
TGFBR1 P36897 1/20 0.36
CNR2 P34972 1/20 0.36
IGF1R P08069 1/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TP53 P04637 2/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
EGFR P00533 1/20 0.35
NT5E P21589 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596261 0.89 IGF1R (0.35) ALOX15MEN1GAAKMT2ATGFBR1
SCHEMBL24596403 0.88 KDM4E (0.47) ALOX15MAPK1LRRK2CNR2IGF1R
SCHEMBL24596284 0.82 IGF1R (0.54) KMT2AIGF1RKDM4ETSHRHSD17B10
SCHEMBL26631704 0.81 ALOX15 (0.40) ALOX15MAPK1MEN1GAAKMT2A
SCHEMBL26631708 0.80 GSK3A (0.36) ALOX15GAALRRK2TGFBR1IGF1R
SCHEMBL24596311 0.78 SYK (0.45) SMN1; SMN2TP53EGFR
SCHEMBL24596400 0.77 IGF1R (0.42) MEN1GAAKMT2ATGFBR1CNR2
SCHEMBL24596360 0.76 LMNA (0.36) TGFBR1IGF1RTSHRAURKA
SCHEMBL24596239 0.76 NR1I2 (0.42) MEN1GAAKMT2AKDM4ENPC1
SCHEMBL24596390 0.74 LMNA (0.45) MEN1KMT2ALRRK2IGF1RKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A ALOX15 4270/4885MAPK1 1249/4885MEN1 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.